Novo Nordisk's success with its GLP-1 receptor agonists, Ozempic and Wegovy, is examined, highlighting the intense competition in the weight-loss drug market. The text explores various factors influencing the company's dominance, including market demand driven by the obesity epidemic, regulatory hurdles and pricing strategies, and internal factors such as strong R&D and strategic alignment. Technological advancements and social trends also played crucial roles. Despite side effects and high costs, the drugs' effectiveness has fueled significant demand.

Ver todos los episodios